BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

National Academy of Sciences Publishes Cancer Findings Of Boston Biomedical Research Institute


3/13/2006 12:59:07 PM

WATERTOWN, Mass., March 13 /PRNewswire/ -- Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world's most frequently cited multidisciplinary scientific periodicals, has published the findings of Dr. Charles P. Emerson, Jr., Ph.D., Senior Scientist and Director, Xingbin Ai, Ph.D. and Ke Lu, M.S. of the not-for-profit Boston Biomedical Research Institute (BBRI) and Dr. Natalia Riobo, a postdoctoral research fellow at the University of Pennsylvania School of Medicine. In this innovative study, Dr. Emerson and his colleagues highlight new potential targets for the therapeutic intervention of a diverse range of human cancers by describing a novel synergistic association between two important cellular signaling pathways.

This research focuses on characterizing a form of cellular communication known as Hedgehog signaling. The Hedgehog signaling pathway is activated when Sonic Hedgehog, a well known signaling molecule, binds to its receptor Patched, ultimately leading to the activation of a family of transcription factors known as Glis (Gli1, Gli2, and Gli3). Normally this pathway regulates fundamental developmental processes such as embryonic tissue patterning and stem cell maintenance. However, inappropriate Hedgehog signaling is causal in a number of important human cancers, including pancreatic, lung, prostate, skin, muscle, and digestive tract cancer -- all of which remain largely untreatable.

"Understanding the key components of the Hedgehog signaling pathway and how it is associated with other cellular signaling pathways is crucial for the development of novel therapeutic approaches to treat this devastating group of cancers. These preliminary findings offer great promise for the development of preventative and curative treatments by identifying new therapeutic targets," said Dr. Emerson. This work was supported by a National Cancer Institute grant.

Boston Biomedical Research Institute is a not-for-profit institution dedicated to the understanding, treatment and prevention of specific human diseases such as cancer, cardiovascular disease, muscular dystrophy, Alzheimer's disease, diabetes and conditions such as obesity and reproductive health problems. For more information visit http://www.bbri.org.

SOURCE

CONTACT: Terence McGowan of Boston Biomedical Research Institute,+1-617-658-7707, mcgowan@bbri.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES